David T Weaver

This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Verastem, Inc.. Active years: 2020-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David T Weaver. Retrieved from https://idiyas.com/inventor/david-t-weaver-ija86nxj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 2 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

2 out of 13

Verastem, Inc.

patents

Years Active: 2020-2023

Loading Chart...

2 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11564927 - Therapeutic compositions, combinations, and methods of use (2023-01-31),

2. 10532056 - Therapeutic compositions, combinations, and methods of use (2020-01-14),

Title: David T Weaver: Innovator in Therapeutic Compositions

Introduction

David T Weaver is a notable inventor based in Needham, MA (US). He has made significant contributions to the field of therapeutic compositions, particularly in the treatment of abnormal cell growth, such as cancer. With a total of 2 patents to his name, Weaver's work is paving the way for advancements in immunotherapy.

Latest Patents

Weaver's latest patents focus on innovative methods that involve administering a FAK inhibitor alongside an immunotherapeutic agent, such as anti-PD-1 or anti-PD-L1. These inventions are particularly useful in treating cancer in mammals, especially humans. His research aims to enhance the effectiveness of cancer treatments by combining these therapeutic agents.

Career Highlights

David T Weaver is currently associated with Verastem, Inc., a company dedicated to developing innovative therapies for cancer treatment. His work at Verastem has allowed him to explore groundbreaking approaches to combat cancer, contributing to the company's mission of improving patient outcomes.

Collaborations

Weaver has collaborated with esteemed colleagues, including Jonathan A Pachter and Jennifer E Ring. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pursuit of effective cancer therapies.

Conclusion

David T Weaver's contributions to the field of therapeutic compositions highlight his commitment to advancing cancer treatment. His innovative patents and collaborations with other experts underscore the importance of teamwork in the fight against cancer.

Profile summary based on public USPTO records.